November 5, 2019
Results of a nationwide survey indicate most hospitals do not employ best practices in glucose control, which leads to increased safety risks, higher readmission rates and significantly greater costs.
According to a recent survey, more than 75% of U.S. hospitals employ an outdated form of insulin therapy inconsistent with recommendations by the American Diabetes Association, American Association of Clinical Endocrinologists, Society of Hospital Medicine and other authoritative sources.
June 4, 2019
New product will be the market’s first and only to enable optimization of ALL diabetes medications, insulin and non-insulin alike.
In spite of greater than 80 medications currently available in the U.S. to treat diabetes, less than half of the estimated 22 million people prescribed one or more are maintaining blood sugar levels within the acceptable range. The consequences not only impact health status and quality of life, they add to the growing economic burden of diabetes estimated in 2017 at $327 billion. With multiple patent allowances for its novel Therapy Advisor® software-as-a-medical-device and active engagement in the FDA 510(k) process, Glytec is poised to improve these clinical and financial outcomes by helping providers more easily and efficaciously select and dose all varieties of diabetes medications. No solution of like kind is currently available, Therapy Advisor® will be the first.
May 23, 2019
The digital therapeutics pioneer is expanding its intellectual property footprint beyond the U.S., gaining worldwide protections for its proprietary diabetes therapy management solutions.
The rise in diabetes is truly a global phenomenon. The World Health Organization has been vocal about the estimated 422 million people living with diabetes, saying: “the prevalence of diabetes is steadily increasing everywhere” and “diabetes and its complications impact harshly on the finances of individuals and their families, and the economies of nations.” Glytec recognizes that optimizing diabetes medications and making insulin a more effective and accessible option stands to benefit not only those living in the U.S, but people around the world. To that end, the company is growing its intellectually property portfolio on an international scale.
October 30, 2018
The popular eBook showcases clinical and financial implications of hypoglycemia, a common occurrence among hospitalized patients that costs the average hospital $1.5 to $5.6 million a year, or more.
Hypoglycemia in the hospital is common, costly, extremely serious and largely preventable, but many c-suite and business office executives are unaware of what it is, why it occurs or the significant impact it has on patient safety, outcomes and economics. A new eBook from Glytec, offered free of charge at the company’s website, shines a light on critical concerns surrounding hypoglycemia and helps healthcare organizations understand how to mitigate risks and initiate optimal prevention strategies. Availability of the eBook is especially timely given the hypoglycemia quality measure currently under development by the Centers for Medicare & Medicaid Services (CMS).
November 8, 2017
New data presented at the 17th Annual Diabetes Technology Meeting observed no diabetes-related readmissions, urgent care visits or emergency department visits within 30 days of hospital discharge when using Glytec’s software.
A prospective quality improvement study led by Eastern Virginia Medical School and presented at the 17th Annual Diabetes Technology Meeting highlights the importance of properly managing transitions of care for patients with diabetes. The study observed that when providers used the Hospital-to-Home (H2H®) module of Glytec’s eGlycemic Management System® to guide insulin regimens prescribed at discharge, patients had no diabetes-related readmissions, urgent care visits or emergency department visits within the first 30 days.
April 26, 2017
Drs. Umpierrez and Cardona publish economic and clinical results of the GLUCO-CABG trial, leveraging Glytec’s Glucommander™ for personalized insulin dosing.
A study from Emory University published in the April 2017 issue of Journal of Diabetes and Its Complications (Cardona, et al. 2017) observes a near-20% reduction in perioperative complications, a 1.2-day reduction in ICU stay and a $3,654 reduction in per-patient hospitalization costs for coronary artery bypass graft (CABG) surgery. The reported outcomes, which included no severe hypoglycemia less than 40 mg/dL, were derived from an intensive glycemic control protocol supported by Glytec’s Glucommander™ for personalized insulin dosing.
July 8, 2016
An electronic glycemic management system (eGMS) may help lower rates of hypoglycemia and lower average blood glucose levels in hospitalized patients compared with usual care, according to a new study.
The aim of this study was to compare hypoglycemia rates in patients managed with an eGMS compared with patients managed by usual care. In this current study, there were 45,335 patients treated with usual care and 13,351 patients treated with eGMS. The target blood glucose was pegged at 100 mg/dL to 180 mg/dL. The researchers evaluated how many patients experiencing mild to moderate hypoglycemia (<70 mg/dL, <60 mg/dL, and <50 mg/dL) and severe hypoglycemia (<40 mg/dL) in the eGMS group compared with the usual care group.
